Ask My Investor AI
Public company · NasdaqPublished company research
NTRA

Identity verified against SEC EDGAR filing 0001104659-26-020881; registered as Natera, Inc., CIK 0001604821.

Natera

Natera is mapped to the Women's health formalization theme as Genetic testing - reproductive health (Panorama NIPT, Horizon carrier screening) alongside oncology (Signatera) and organ-health.. Medium and partial. Reproductive health is Natera's founding franchise, but recent growth has been oncology-led (Signatera), so women's-health is a declining share of the growth mix. Natera IR pages confirm the Panorama/Horizon and Signatera product lines; current segment revenue was not retrieved. Theme materiality is stated separately and, where not independently verified, is marked accordingly.

Ask follow-up research
Reviewed company research · researched 2026-07-22 · not an individual investment recommendation
Listing
public
Ticker
NTRA
Exchange
Nasdaq
HQ
—
Currency
USD
SEC CIK
0001604821
Investment case

How this company captures the theme economics

Competitive position

Medium and partial. Reproductive health is Natera's founding franchise, but recent growth has been oncology-led (Signatera), so women's-health is a declining share of the growth mix. Natera IR pages confirm the Panorama/Horizon and Signatera product lines; current segment revenue was not retrieved. Company-specific competitive positioning is assessed at the theme level and awaits deeper primary research.

Scarce assets

Scarce assets in this value chain include reimbursement and coverage decisions (state ivf/fertility mandates, employer benefit design, cms/medicaid) - the gating variable for the whole theme., specialist capacity: reproductive endocrinologists/fertility clinics, urogynecology, maternal-fetal medicine., proprietary clinical data and validated assays/algorithms (nipt content, hpv assays, ai mammography)..

Products, segments, and customers

Natera operates in Women's health formalization. Segment- and product-level detail is pending company-specific research.

Theme capture

Medium and partial. Reproductive health is Natera's founding franchise, but recent growth has been oncology-led (Signatera), so women's-health is a declining share of the growth mix. Natera IR pages confirm the Panorama/Horizon and Signatera product lines; current segment revenue was not retrieved.

Conditions

What must be true

  1. Latest 10-Q: reproductive-health revenue, Panorama NIPT volumes and ASP trends; competitive/pricing dynamics in NIPT and carrier screening.
  2. The exposure described for Natera must be confirmed as financially material in official filings.

Identifiable catalysts

  • Forthcoming quarterly and annual issuer filings
  • Theme-level catalysts detailed in the Women's health formalization brief
Theme materiality

1 mapped theme

Exposure statements are evidence-qualified. Materiality is only claimed where disclosure supports it.

Genetic testing - reproductive health (Panorama NIPT, Horizon carrier screening) alongside oncology (Signatera) and organ-health.

Women's health formalization

Medium and partial. Reproductive health is Natera's founding franchise, but recent growth has been oncology-led (Signatera), so women's-health is a declining share of the growth mix. Natera IR pages confirm the Panorama/Horizon and Signatera product lines; current segment revenue was not retrieved.

Evidence
Fetched Natera news/IR landing pages confirm product lines but not financials (pages were navigation-only; SEC filings not retrievable in-session).
Materiality
not assessed — Reproductive-health revenue and volume not established from a fetched primary figure this session; product relevance confirmed, magnitude not.
Financial evidence

Official SEC filing evidence

Reference period: FY2025.

  • Operating income$-310 million
    FY2025[1]
  • EBITDA$-268 million
    FY2025[1]
  • Diluted EPS$-1.52
    FY2025[1]
  • Operating cash flow$215 million
    FY2025[1]
  • Free cash flow$109 million
    FY2025[1]

Limitation: Filing evidence establishes scale, profitability, cash generation, and leverage. Market-derived valuation is withheld until a licensed market-data feed is connected, and theme materiality is stated separately.

Risks

Material risks and break conditions

Material risks

  • Reimbursement is discretionary and employer/state-budget-dependent; mandate momentum can stall (e.g., a governor vetoed a broader Medicaid fertility mandate) and Medicaid coverage remains rare (only ~3 states).
  • Customer-acquisition costs in direct-to-consumer femtech and virtual care can overwhelm care economics - an explicit thesis-break condition and a real risk for private platforms.

Thesis-break conditions

  • Reimbursement remains weak: state fertility-mandate expansion stalls or retreats and Progyny covered-lives/client growth turns negative for two-plus consecutive quarters.
  • Care economics break: fertility-benefit or digital-platform gross margins compress materially, or Progyny's historically high client retention falls below ~95%, or private femtech marks down on CAC-driven losses.
Investability conclusion

Where the evidence lands

Identity and filing financials are established; theme materiality is not independently verified. This is a filing-backed research profile with deeper company-specific research pending, and is not a personalized recommendation.

Next diligence

  1. Latest 10-Q: reproductive-health revenue, Panorama NIPT volumes and ASP trends; competitive/pricing dynamics in NIPT and carrier screening.
Source ledger

Identity and evidence sources

Identity was verified against official issuer, filing, exchange, or regulator sources where available.

  1. Natera, Inc. FY2025 Form 10-KSEC EDGAR · primary · published 2026-02-27 · accessed 2026-07-22